Blanchard, Laurine S.Van Belkum, AlexDechaume, DominiqueArmstrong, Thomas P.Emery, Christopher L.Ying, Yun X.Kresken, MichaelPompilio, MarionHalimi, DianeZambardi, Gilles2023-05-152023-05-152022Blanchard LS, Van Belkum A, Dechaume D, et al. Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales. J Clin Microbiol. 2022;60(1):e0183121. doi:10.1128/JCM.01831-21https://hdl.handle.net/1805/32956Plazomicin (PLZ), brand name ZEMDRI (Cipla Therapeutics), is a novel aminoglycoside antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections including pyelonephritis. ETEST® is a gradient diffusion method that represents an alternative to the more laborious broth micro-dilution (BMD) method for performing antimicrobial susceptibility testing (AST). A multi-center evaluation of the performance of the new ETEST PLZ (bioMérieux) was conducted in comparison with BMD following FDA and International Standards Organization (ISO) recommendations using FDA-defined breakpoints. Clinical isolates of Enterobacterales (n = 598) were included. Fifty-three isolates were resistant to PLZ according to BMD. Overall, the ETEST PLZ demonstrated 99.0% essential agreement (EA), 92.8% category agreement (CA), 1.9% very major errors (VME), 0% major errors (ME), and 7.0% minor errors (mE) with both clinical and challenge isolates of Enterobacterales. The VME was found for a single Serratia marcescens strain. Individual species demonstrated EA rates ≥ 90%. In conclusion, we report that ETEST PLZ represents an accurate tool for performing PLZ AST of Enterobacterales.en-USAttribution 4.0 InternationalAntimicrobial susceptibility testingGradient methodsPlazomicinETESTEnterobacteralesPlazomicin resistance mechanismsArticle